In this FDA staff article, “Cancer risk associated with lorcaserin — The FDA’s review of the CAMELLIA-TIMI 61 trial”, which was published by the New England Journal of Medicine (NEJM), the early 2020 FDA Belviq recall decision was explained. Essentially, this FDA action after a careful analysis of Belviq safety data that revealed excess … [Read more...]
Zantac Recall: Chemical NDMA In Zantac Pills Can Cause Cancers
The contaminant chemical NDMA in Zantac pills is a substance that could cause cancer of the: pancreas (pancreatic cancer), stomach, colon, rectum (rectal cancer), bladder, or kidney (renal cancer). On April 1, 2020, the FDA announced that it was requesting a Zantac recall due to the presence of NDMA in Zantac and all other medications containing … [Read more...]
After Drug Recall Belviq Lawsuits Alleging Failure To Warn About Cancer
Following the Belviq recall in February 2020 some of those patients on Belviq developing cancer filed Belviq lawsuits alleging a failure to warn about the risk of cancer associated with Belviq. We are investigating possible Belviq lawsuits that involve patients on Belviq developing cancer. At the present time, our focus for these Belviq lawsuits … [Read more...]
Belviq Recall Due To Certain Cancers: Pancreatic, Colon, Rectal, And Lung
The diet drug Belviq is being withdrawn from the US market because a Belviq safety clinical trial shows an increased occurrence of cancer cases. This February 2020 Belviq FDA Drug Safety Communication announced the Belviq recall, “FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market”, and noted that … [Read more...]
Zantac Cancer Lawsuits Filed After FDA Warnings About NDMA In Ranitidine
Zantac cancer lawsuits are for being filed for patients diagnosed with certain types of cancer after using Zantac (ranitidine) for heartburn associated with acid indigestion and sour stomach. According to medical research, some of the cancers associated with Zantac use due to NDMA exposure include: Stomach cancerColon cancerRectal … [Read more...]
Pancreatic Cancer: Side Effect Of Onglyza, Nesina, Tradjenta, Other DPP-4 Inhibitor Diabetes Drugs?
There is new medical research concerning pancreatic cancer linked to diabetes medicines in the DPP-4 inhibitor drug class. In more detail, the use of dipeptidyl peptidase-4 inhibitors (DPP-4i) diabetes medicines may be associated with an increased risk for pancreatic cancer in patients with newly diagnosed type 2 diabetes. This finding comes … [Read more...]
Current Number Of Lawsuits Filed In The Four Diabetes Drugs Federal Court MDL Cases
From the February 15, 2018 version of this document, “MDL Statistics Report – Distribution of Pending MDL Dockets by Actions Pending” (accessed 2/21/18), published by the United States Judicial Panel on Multidistrict Litigation (JPML), we get the current number of cases filed in each of the four federal court Multidistrict Litigation (MDL) cases … [Read more...]
Saxenda May Increase Risks Of Pancreatic Cancer / Pancreas Malignancy
While the current Prescribing Information, or drug label, for Saxenda (accessed 1/30/18) has a so-called “Black-Box Warning” for the risk of thyroid C-cell tumors, a type of thyroid cancer, and pancreatitis is mentioned in the Warnings and Precautions section, there is nothing about an increased risk of pancreatic cancer. In 2014, the FDA … [Read more...]
Pancreatic Cancer Lawsuits Reinstated for Incretin-Based Diabetes Drugs
Background Among the several different types of therapies indicated for treating type 2 diabetes are increatin mimetics. The medications approved by the FDA that fall into this class of drugs are: Byetta (exenatide) Bydureon (exenatide) Januvia (sitagliptin) Janumet (sitagliptin) Victoza (liraglutide) Previous scientific … [Read more...]
FDA Concern About Whether Victoza Is Associated With Pancreatic Cancer
In advance of the June 20, 2017 FDA Advisory Committee meeting to discuss Novo Nordisk’s supplemental New Drug Application (sNDA) for approval of Victoza® (liraglutide) injection, we reviewed the FDA Briefing Document for this Endocrinologic and Metabolic Drugs Advisory Committee Meeting (EMDAC), which includes a section titled “ONCOLOGY CONSULT: … [Read more...]